CTOs on the Move

Northwest Bioanalytical

www.nwtinc.com

 
Northwest Bioanalytical is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.nwtinc.com
  • 1141 E 3900 S
    Salt Lake City, UT USA 84124
  • Phone: 801.293.2366

Executives

Name Title Contact Details

Similar Companies

Vium

Vium is the first company to create a living informatics platform for preclinical in vivo drug research.

Prevail Therapeutics

At Prevail Therapeutics, we are pioneering innovative therapies that aim to cure neurodegenerative disorders, such as Parkinson`s disease. Our mission is to translate breakthrough advances in human genetics and gene therapy technology into life-changing medicines that slow, stop and reverse the neurodegenerative process. Our novel gene therapies target patients with urgent unmet needs, where there are currently no available therapies to change the progressive course of their diseases. Prevail was formed in 2017, and as an emerging biotechnology company, we are growing rapidly. We are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.

IDx Technologies

IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare.

Arbutus Biopharma

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio.

FASgen

FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.